Testing a new eye injection for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diabetes (type 1 or 2).
- Your latest blood sugar test (HbA1c) must be 12% or lower.
- In the study eye, you have swelling in the center of the retina that is at least 325 micrometers thick, and your vision is between 20/50 and 20/200 (65 to 35 letters on an eye chart).
- You cannot have had any eye injections or implants (like anti-VEGF or steroid treatments) before joining (if you are in Parts 1 or 2 of the study).
- You cannot have uncontrolled high blood pressure, active eye inflammation, or a history of certain eye conditions like uveitis or severe diabetic retinopathy in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a drug called faricimab (an injection into the eye) for treating diabetic macular edema, a condition where fluid builds up in the retina and causes vision loss. It is specifically for people of South Asian origin and aims to see how well and how long the treatment works and if it is safe.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.